← Back to Clinical Trials
Recruiting NCT07055113

NCT07055113 Adapting Rehabilitation Delivery for Maximum Impact at Home-2 (ReDI-2)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07055113
Status Recruiting
Phase
Sponsor University of Alberta
Condition Knee Osteoarthritis
Study Type INTERVENTIONAL
Enrollment 270 participants
Start Date 2025-07-09
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Individual-based Virtual Physical Therapy ProgramGroup-based Virtual Physical Therapy Program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 270 participants in total. It began in 2025-07-09 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

People who live in rural areas and have hip or knee arthritis can have difficulty receiving physical therapy (PT) close to home. Living with hip or knee arthritis can make doing daily activities and being physically active difficult. This can lead to other health conditions, such as becoming overweight, or lessen enjoyment of life. We will compare 2 programs that allow physical therapists to treat rural residents in their own home to each other and to usual care. Usual care is the care that is typically provided to people living with hip or knee arthritis. For the first 12 weeks, participants will continue usual osteoarthritis (OA) care and then complete the standardized questionnaires again. Then, they will be randomized to either Individual (IPT) or Group-based PT (GPT). Over 12-weeks, therapists will meet virtually with patients using Zoom so that patients and therapists can see each other. The program will be either a class or one-on-one with a therapist. In the class, participants will still receive private one-to-one time with the therapist using a Zoom 'breakout' room. Therapists in both groups will help patients do exercises correctly in their home. Patients can also see and talk to the therapists to discuss their challenges in living with OA and set personalized goals including pain management, participating in valued daily activities, keeping healthy (diet, sleep) and being active. Both programs will allow patients who sometimes cannot access physical therapy to receive care in their home.

Eligibility Criteria

Inclusion Criteria: * Patient with confirmed hip or knee OA, but deemed to not require total joint arthroplasty (i.e., not on the surgical waitlist) * Not currently be attending physiotherapy * Reside outside of Edmonton or nearby communities * English-speaking * with access to a Zoom-friendly device (smart phone, tablet, laptop). Exclusion Criteria: • Patients who are not meeting the inclusion criteria are not eligible.

Contact & Investigator

Central Contact

Lauren Beaupre, PT, PhD

✉ lauren.beaupre@ualberta.ca

📞 780-492-8626

Frequently Asked Questions

Who can join the NCT07055113 clinical trial?

This trial is open to participants of all sexes, studying Knee Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07055113 currently recruiting?

Yes, NCT07055113 is actively recruiting participants. Contact the research team at lauren.beaupre@ualberta.ca for enrollment information.

Where is the NCT07055113 trial being conducted?

This trial is being conducted at Edmonton, Canada.

Who is sponsoring the NCT07055113 clinical trial?

NCT07055113 is sponsored by University of Alberta. The trial plans to enroll 270 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology